ID   MZ-PC-1
AC   CVCL_1434
AS   CVCL_A657
SY   MZPC-1; MZ1-PC; MZ1PC; MainZ-Pancreatic Cancer-1
DR   CLO; CLO_0037111
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_1434
DR   Cell_Model_Passport; SIDM00053
DR   ChEMBL-Cells; CHEMBL3308242
DR   ChEMBL-Targets; CHEMBL2366204
DR   Cosmic; 753595
DR   Cosmic; 948732
DR   Cosmic-CLP; 753595
DR   DepMap; ACH-002164
DR   EGA; EGAS00001000978
DR   GDSC; 753595
DR   GEO; GSM1670139
DR   IARC_TP53; 21522
DR   LINCS_LDP; LCL-1795
DR   PharmacoDB; MZ1PC_975_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1434
DR   Wikidata; Q54907230
RX   DOI=10.4172/2324-9293.1000104;
RX   PubMed=7599790;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=29444439;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: 45 hours (PubMed=7599790).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg209Lysfs*6 (c.626_627delGA); ClinVar=VCV000372539; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.66%; Native American=0%; East Asian, North=2.92%; East Asian, South=0%; South Asian=1.85%; European, North=62.36%; European, South=32.2% (PubMed=30894373).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11,12
ST   D16S539: 11,12
ST   D5S818: 10,11
ST   D7S820: 9,10
ST   TH01: 6,8
ST   TPOX: 8
ST   vWA: 18
DI   NCIt; C9120; Pancreatic ductal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_VU73 ! MZ-1-EBV-B
SX   Male
AG   46Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 31
//
RX   DOI=10.4172/2324-9293.1000104;
RA   Wagenhauser M.U., Ruckert F., Niedergethmann M., Grutzmann R.,
RA   Saeger H.-D.;
RT   "Distribution of characteristic mutations in native ductal
RT   adenocarcinoma of the pancreas and pancreatic cancer cell lines.";
RL   Cell Biol. Res. Ther. 2:1000104.1-1000104.5(2013).
//
RX   PubMed=7599790; DOI=10.1007/BF00191347;
RA   Heike M., Rohrig O., Gabbert H.E., Moll R.,
RA   Meyer zum Buschenfelde K.-H., Dippold W.G., Knuth A.;
RT   "New cell lines of gastric and pancreatic cancer: distinct morphology,
RT   growth characteristics, expression of epithelial and immunoregulatory
RT   antigens.";
RL   Virchows Arch. 426:375-384(1995).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051;
RA   Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W.,
RA   Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.A.,
RA   Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E.,
RA   Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C.,
RA   Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H.,
RA   McCormick F.;
RT   "Differential effector engagement by oncogenic KRAS.";
RL   Cell Rep. 22:1889-1902(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//